Deridre Kelly/X
Nov 2, 2024, 19:05
Deridre Kelly: Anti–PD-L1 and TKI in anaplastic thyroid cancer
Deridre Kelly, Medical Oncologist at Mater Misericordiae University Hospital, shared a post on X:
“Immuno Oncology: Anti–PD-L1 and TKI in anaplastic thyroid cancer.
Median OS: 19 mosBRAF V600E-mutated patients: 43 mos (50% ORR)
Longest OS in ATC history!
Targeted and immunotherapy synergy outcomes.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 19:36
Apr 19, 2025, 19:17
Apr 19, 2025, 19:01
Apr 19, 2025, 18:42
Apr 19, 2025, 18:29
Apr 19, 2025, 17:53
Apr 19, 2025, 17:17